ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1828

In Vivo Cartilage-Specific Deletion Of Ephrin-B2 In Mice Results In Developmental Locomotory Defects Associated With Hip Bone Abnormality

Gladys Valverde-Franco1, Bertrand Lussier2, David Hum1, Jiangping Wu3, Jean-Pierre Pelletier1, Mohit Kapoor1 and Johanne Martel-Pelletier1, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 2Department of Clinical Sciences, Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, QC, Canada, 3Laboratory of Immunology, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Bone, Hip and mouse model

  • Tweet
  • Email
  • Print
Session Information

Title: Biology and Pathology of Bone and Joint (Bone and Arthritis)

Session Type: Abstract Submissions (ACR)

Background/Purpose: The ephrins and their related receptors comprise the largest subfamily of receptor protein-tyrosine kinases and have been implicated in mediating developmental events. We have previously demonstrated that a member of the ephrin family, ephrin-B2, plays a role in knee joint pathology associated with osteoarthritis (OA). Specifically, we have shown a deregulation in the production of the receptor EphB4 and its specific ligand ephrin-B2 in human subchondral bone and cartilage, and in vitro activation of this system or in vivo overexpression of EphB4 positively impacts the pathological process of OA. The aim of this study was to comprehensively delineate the in vivo role of ephrin-B2 in musculoskeletal growth and development using cartilage-specific ephrin-B2 knockout mice.

Methods: Cartilage-specific ephrin-B2 knockout (ephrin-B2KOCRE) mice were generated using the LoxP-Cre system. The effect of ephrin-B2 genetic deletion was evaluated on bone development using a combination of techniques including macroscopic, histologic, morphometric, radiological, densitometer, and micro-computed tomography (micro-CT). Analyses were performed on postnatal days 0, 15, and 21 (P0, P15, P21), on 8-week-old cartilage-specific ephrin-B2KOCREmice, and in littermates with no Cre as controls.

Results: Data showed that the ephrin-B2KOCRE mice exhibited developmental defects leading to abnormal locomotory patterns. Ephrin-B2KOCRE mice at P15 exhibited reduced weight (p<0.002) and length (p<0.01) and, most importantly, limping and dragging of limbs apparent from the time they started to walk (about 2-3 weeks of age). Interestingly, the hip of ephrin‑B2KOCRE mice displayed abnormalities associated with smaller pelvic width (p<0.03) and hip bones (p<0.01), as well as reduced acetabular rim length (p<0.05) and angle (p<0.05). In addition, ephrin-B2KOCRE mice had significantly smaller femur (p<0.03) and tibia length (p<0.01) and reduced bone mineral density in the total skeleton (p<0.02), femur (p<0.03) and spine (p<0.04). Micro-CT analyses revealed that the distal femur and proximal tibia in ephrin‑B2KOCREmice had a significantly decreased bone volume/tissue volume (BV/TV; p<0.03, p<0.02), trabecular thickness (TbTh; p<0.02, p<0.02), and trabecular separation (TbS; p<0.03, p<0.05).

Conclusion: This study was the first to show that in vivo ephrin-B2 is essential for normal bone growth and development and that conditional cartilage-specific ephrin-B2 deficiency leads to significant alterations in hip bones resulting in developmental locomotory defects. The changes in the long bones are probably a secondary effect of the hip loading force abnormalities.


Disclosure:

G. Valverde-Franco,
None;

B. Lussier,
None;

D. Hum,
None;

J. Wu,
None;

J. P. Pelletier,
None;

M. Kapoor,
None;

J. Martel-Pelletier,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-vivo-cartilage-specific-deletion-of-ephrin-b2-in-mice-results-in-developmental-locomotory-defects-associated-with-hip-bone-abnormality/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology